panobacumab (KBPA101) is a monoclonal antibody developed by Kenta (Switzerland). The results of a clinical phase IIA (optimization of dose and toxicity assessment) I have been presented on the congress of clinical chemistry and infectious diseases at San Francisco. The
panobacumab is a humanized monoclonal antibody (ending in-umab) against Pseudomonas aeruginosa, a Gram-resistant strains with many antibiotic, and involved in about 25% of ventilator-acquired pneumonia breathing (VAP), and in many nosocomial pneumonia (NP), both indications of potential panobacumab. The antibody was developed by a process owned by the company Kenta named MablgX.
Test Results: 100% cure of the 13 patients treated by a complete cycle, against a normal mortality of 33 to 50% in VAP.
Kenta now trying to sell the antibody so that it is retested and then placed on the market.
http://www.caducee.net/breves/breve.asp?idb=9586&mots=all
0 comments:
Post a Comment